Which laboratory tests should be obtained for a patient with a cauterized hematoma whose hemoglobin and hematocrit are still decreasing?

Laboratory Evaluation for Persistent H&H Drop After Hematoma Cauterization

When hemoglobin and hematocrit continue to decline despite cauterization of a hematoma, you must immediately obtain a complete blood count with differential, coagulation panel (PT/INR, aPTT, fibrinogen), platelet count, and consider point-of-care viscoelastic testing (TEG/ROTEM) to detect ongoing bleeding and coagulopathy. 1

Essential Initial Laboratory Tests

Core Hematologic Assessment

• Serial hemoglobin and hematocrit measurements should be obtained every 4 hours or after significant clinical change to monitor the rate and extent of ongoing blood loss 1
• Complete blood count with red cell indices (MCV, MCH, MCHC, RDW) and white blood cell differential to assess bone marrow response and rule out concurrent hematologic abnormalities 2, 3
• Platelet count is critical because thrombocytopenia (<50,000/mm³ in trauma, <100,000/mm³ with ongoing bleeding) significantly increases bleeding risk and mortality 1, 2
• Reticulocyte count helps evaluate bone marrow response to blood loss 2

Coagulation Studies

• Prothrombin time (PT/INR) and activated partial thromboplastin time (aPTT) to detect factor deficiencies or inhibitors 1, 3
• Fibrinogen level should be maintained >1.0 g/L (ideally >1.5 g/L) during active bleeding; fibrinogen deficiency develops early when plasma-poor red cells are used for replacement 1
• Thrombin time (TT) to detect disseminated intravascular coagulation (DIC), heparin presence, or hepatopathy 3
• D-dimer and fibrin degradation products are the most specific parameters for DIC and reflect fibrinolysis of cross-linked fibrin 2

Point-of-Care Viscoelastic Testing

Advantages Over Traditional Coagulation Tests

• Thromboelastography (TEG) or rotational thromboelastometry (ROTEM) provide rapid turnaround time (5-10 minutes) and information on all phases of coagulation, unlike PT/INR and aPTT which were designed for monitoring anticoagulants, not acute hemorrhage 1
• ROTEM/TEG clot amplitude at 5 minutes (CA5) is a validated marker for acute traumatic coagulopathy: EXTEM CA5 ≤40 mm predicts massive transfusion with 72.7% sensitivity, and FIBTEM CA5 ≤9 mm predicts it with 77.5% sensitivity 4
• Point-of-care hemoglobin testing (blood gas analysis or HemoCue) correlates well with laboratory measurements and provides immediate results 1

Specific ROTEM/TEG Thresholds for Transfusion

• Cryoprecipitate (fibrinogen replacement): FIBTEM CA5 <10 mm or functional fibrinogen TEG MA <20 mm 1
• Platelet transfusion: EXTEM CA5 – FIBTEM CA5 <30 mm or rTEG MA – FF TEG MA <45 mm 1
• Fresh frozen plasma: EXTEM CA5 >40 mm plus EXTEM CT >80 s 1
• Tranexamic acid: EXTEM LI30 <85% or rTEG LY30 >10% 1

Additional Critical Laboratory Tests

Metabolic and Perfusion Markers

• Serum lactate and base deficit are sensitive markers to estimate the extent of traumatic-hemorrhagic shock and monitor response to resuscitation 1
• Blood gas analysis provides immediate assessment of pH, base deficit, and hemoglobin, helping identify the "lethal triad" of hypothermia, acidosis, and coagulopathy 1

Iron Status and Hemolysis

• Serum ferritin and transferrin saturation to evaluate iron stores, especially if ongoing bleeding is suspected 2
• Peripheral blood smear review to assess red cell morphology and identify abnormalities that may explain the H&H drop 2

Critical Timing Considerations

• Hemoglobin concentration does not fall for several hours after acute hemorrhage because hemodilution from fluid shifts takes time; therefore, initial H&H may underestimate true blood loss 1, 5
• Change in hematocrit (ΔHct) during initial assessment is more reliable than single measurements: ΔHct ≥6 during resuscitation is highly suspicious for ongoing blood loss (89% sensitivity, 95% specificity), even with ongoing fluid administration 5
• Repeat coagulation studies every 4 hours or after each one-third blood volume replacement to guide ongoing hemostatic therapy 1

Common Pitfalls to Avoid

• Do not rely solely on initial H&H values in acute bleeding—fluid shifts are rapid after hemorrhage, and serial measurements are essential 5
• Do not delay viscoelastic testing if available—traditional coagulation tests have slow turnaround times and do not reflect the dynamic clinical situation during ongoing hemorrhage 1
• Do not withhold tranexamic acid therapy while waiting for viscoelastic results—administer empirically if fibrinolysis is suspected 1
• Do not overlook platelet dysfunction in patients taking antiplatelet agents (aspirin, clopidogrel)—platelet function testing may be indicated 1

Algorithmic Approach

1. Obtain immediate labs: CBC with differential, platelet count, PT/INR, aPTT, fibrinogen, lactate, base deficit 1
2. If viscoelastic testing available: Run ROTEM/TEG immediately to guide targeted blood product therapy 1, 4
3. Repeat H&H every 4 hours or sooner if clinical deterioration occurs 1
4. Calculate ΔHct: If ≥6 during resuscitation, strongly suspect ongoing bleeding 5
5. Check fibrinogen: If <1.0 g/L, transfuse cryoprecipitate immediately 1
6. Monitor platelets: Maintain >50,000/mm³ (>100,000/mm³ with ongoing bleeding or traumatic brain injury) 1
7. Assess for DIC: Rising D-dimer, falling fibrinogen, prolonged PT/aPTT/TT indicate consumptive coagulopathy requiring aggressive component therapy 2, 3